DUBLIN — April 2, 2020 — Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has acquired Curzion Pharmaceuticals, Inc., a privately held development-stage biopharma company, and its development-stage oral...
Arthur Klausner will be a panelist at “The Venture Prognosis – what’s driving investment preferences?” at the Life Sciences & Healthcare Venture Summit on October 23, 2007 in NYC
News | 10. 23. 2007
